Diener, Hans-Christoph http://orcid.org/0000-0002-6556-8612
Article History
First Online: 1 February 2019
Competing interests
: H.C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Addex Pharma, Alder, Allergan, Almirall, Amgen, Autonomic Technology, AstraZeneca, Bayer Vital, Berlin Chemie, Böhringer Ingelheim, Bristol-Myers Squibb, Chordate, Coherex, CoLucid, Electrocore, GlaxoSmithKline, Grünenthal, Ipsen, Janssen-Cilag, Labrys Biologicals, Lilly, La Roche, 3M Medica, Medtronic, Menerini, Minster, Merck Sharp & Dohme, Neuroscore, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi, St. Jude, Teva and Weber & Weber. Financial support for research projects was provided by Allergan, Almirall, AstraZeneca, Bayer, Electrocore, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme and Pfizer. His headache research is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. H.C.D. has no ownership interest and does not own stocks of any pharmaceutical company. H.C.D. serves on the editorial boards of <i>Cephalalgia</i> and <i>Lancet Neurology</i>. H.C.D. chairs the Clinical Guidelines Committee of the German Society of Neurology and is a member of the Clinical Trials Committee of the International Headache Society.